Nurmemmedov Lab

Laboratory of Preclinical Pharmacology of Novel Therapeutics
Principal Investigator: Elmar Nurmemmedov, PhD, MBA

 

Research

- Mechanism of action and acquired resistance of novel therapeutic modalities (small molecules, Protacs, peptides);
- Method development for efficient drug discovery, such as biophysical and cellular methods;
- Challenging drug targets and novel methodologies for targeting;
- Utilization of chem-informatics, bio-informatics and genomics tools for interrogation of novel drug targets and therapeutic candidates.

Ongoing and recently completed projects:

Uncle Cory Foundation                                                                                                       06/2018 – 06/2020

Targeted inhibition of beta-catenin in medulloblastoma

Role: PI

Fashion and Footwear Association of New York (FFANY)                                          01/2021 – 12/2022

Development of the first-in-class inhibitor of chromatin remodeler CHD4 for triple-negative breast cancer

Role: PI

NIH-NCI 1R37CA261987-01 (Bitler BG, PI)                                                        07/09/2021 – 06/30/2026

Targeting Wnt signaling in therapy-resistant ovarian cancer

Role: Co-I/Sub-recipient PI